An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a retrospective, observational study looking at real-world prescription data in Australia. The study focuses on adult men with metastatic hormone-sensitive prostate cancer (mHSPC), a type of prostate cancer that has spread but still responds to hormone therapy. The main goal is to understand the treatment patterns, characteristics, and outcomes for patients who are receiving a class of drugs called Androgen Receptor Pathway Inhibitors (ARPIs), such as darolutamide, enzalutamide, apalutamide, or abiraterone. These drugs are often used in combination with standard Androgen Deprivation Therapy (ADT). The research will use two large, de-identified Australian prescription databases: the Pharmaceutical Benefits Scheme (PBS) and the NostraData retail pharmacy dataset. By analyzing this information, the study aims to describe how these treatments are being used over time, including what proportion of patients receive doublet therapy (ARPI + ADT) or triplet therapy (ARPI + ADT + docetaxel chemotherapy). It will also describe the characteristics of the patients receiving these therapies, such as their age and location. Secondary goals include understanding how well patients adhere to their prescribed ARPI treatment and tracking any changes in medication dosage over time. Since the study uses existing, anonymized data, there is no direct contact with patients and individual patient consent is not required. The findings will provide valuable real-world insights into the use of ARPIs in Australia, which can help inform clinical practice and improve care for men with mHSPC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni z rakiem prostaty, który się rozprzestrzenił, ale wciąż reaguje na leczenie hormonalne.
- •Pacjenci, którzy po raz pierwszy otrzymali jeden z badanych leków na raka prostaty w określonym czasie.
- •Pacjenci, którzy w momencie rozpoczęcia leczenia mieli co najmniej 18 lat.
- •Pacjenci, dla których dostępnych jest co najmniej 12 miesięcy danych sprzed rozpoczęcia leczenia.
- •Pacjenci, dla których dostępnych jest co najmniej 3 miesiące danych po rozpoczęciu leczenia.
✗ Disqualifies
- •Pacjenci, którzy wcześniej przyjmowali którykolwiek z badanych leków.
- •Pacjenci, u których wcześniej stwierdzono formę raka prostaty oporną na leczenie hormonalne (niezależnie czy się rozprzestrzenił, czy nie).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 6, 2026
- Sex
- Male only
Locations (1)
Bayer
Pymble, Australia
Trial contact
Bayer Clinical Trials Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.